on december 28, the 2nd meeting of the 10th session of the council of jiangsu medical association (jsma), jsma 2018 working conference and 2017 jiangsu medical technology award presentation ceremony were held in nanjing. the meeting reviewed and passed jsma 2017 work summary and 2018 work plan, and announced the 2017 jiangsu medical technology award. jsma chairwoman ms. wang yonghong and other seniors attended the meeting. other attendees included experts and principals of jsma’s local branches and award winning scientists.
at the meeting, jsma and hansoh pharmaceutical group signed a strategic cooperation agreement: during the five years from 2018 to 2022, the group will continue as the exclusive sponsor for the selection of jiangsu medical technology award. in a gesture to appreciate hansoh’s efforts in supporting the award, jsma granted hansoh the honor of “best sponsor for 2010-2017 jiangsu medical technology award”. the group’s executive vice president ms. fu caiyun accepted the prize on behalf of the company.
jiangsu medical technology award is the highest technology award in the province’s healthcare industry. it is set up and hosted by jsma for scientists and units that make outstanding contribution to preventing disease and improving people’s health in the fields of basic medicine science, clinic medicine, preventive medicine and hygiene, and pharmacy. since establishment of the award in 2010, hansoh has been serving as exclusive sponsor for 8 consecutive years. during the 8 years, the award has commended 308 healthcare achievements and played an important role in promoting the development of talents and healthcare sciences, and in enhancing people’s health indicators. hansoh’s role of taking social responsibilities has also won appraisal from the medical professionals.
with the mission of “serve the society and build a healthy world”, hansoh has been actively devoted to the development of the nation’s healthcare undertakings in the past decades, trying to provide to society with quality drugs and services, and has grown into one of the top 23 best pharmaceutical enterprises in china. in terms of csr, besides serving as the exclusive sponsor for jiangsu medical technology award, hansoh also invested significant amount of funds to launch “the great love • mental health”, a non-profit special fund for mental health care in china, and “special fund for health professionals care” to support the undertakings of mental health care and improve physical and mental health of healthcare professionals. besides, hansoh also vigorously supports academic events held by medical associations of national, provincial and municipal levels, and sponsors and sets up awards in universities to constantly contribute to talent development for the industry.
in the future, under the guidance of the spirit of the 19th cpc national congress, hansoh pharma will serve the supply-side structural reform of medical industry with all its strengths, and continue to produce more quality and effective drugs to benefit the people and give back to society. it will be, as it always has been, strengthening its cooperation with associations and make bigger contribution to the thriving of china’s healthcare undertakings.